title: Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.
abstract: Type 2 diabetes mellitus (DM) is a major cardiovascular (CV) risk factor and, as such, is considered a coronary artery disease risk equivalent. Although glycemic control is associated with decreased CV events epidemiologically, many prospective clinical trials have failed to conclusively demonstrate that aggressive glycemic control improves the CV prognosis of patients with type 2 DM, especially those with long-standing DM. Many therapies for type 2 DM with widely divergent mechanisms of action are available. Some of these drugs, in addition to their glucose-lowering actions, have properties that may reduce or increase CV events. Agents that lower both insulin resistance and postprandial hyperglycemia while at the same time avoiding hypoglycemia may be beneficial for CV health. This article reviews the evidence regarding the use of these agents and appropriate glycemic control targets for improving the adverse CV prognosis associated with type 2 DM. We conducted a systematic review of English articles using MEDLINE and the Cochrane Controlled Trials Register (1970-2010) using the following search terms: cardiovascular disease, randomized trials, hypoglycemia, and insulin resistance.
authors.affiliation: Mid America Heart and Vascular Institute and University of Missouri-Kansas City, Kansas City, MO, USA.
authors.forename: James H
authors.initials: JH
authors.lastname: O'Keefe
authors.forename: Mohammad
authors.initials: M
authors.lastname: Abuannadi
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Lavie
authors.forename: David S H
authors.initials: DS
authors.lastname: Bell
mesh_terms: D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000503:physiopathology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000503:physiopathology / Q000517:prevention & control; D019518:Postprandial Period; D011379:Prognosis; D012306:Risk
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents